Clinical Trial Update: A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous MK-3222 in Participants With Moderate-to-Severe Chronic Plaque Psoriasis (MK-3222-012) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating subcutaneous MK-3222 for plaque-type psoriasis has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque-type Psoriasis

Drugs mentioned

• MK-3222

Snippet

Sponsor: Sun Pharmaceutical Industries Limited | Conditions: Plaque-type Psoriasis | Phase 3 | Status: WITHDRAWN